Format

Send to

Choose Destination
Z Rheumatol. 2018 Nov;77(9):824-832. doi: 10.1007/s00393-018-0419-4.

TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis.

Author information

1
Department of Rheumatology, Hospital for Rheumatic Diseases, Division of Rheumatology, Hanyang University, Hanyang, Korea (Republic of).
2
Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, 136-705, Seoul, Seongbuk-gu, Korea (Republic of). lyhcgh@korea.ac.kr.

Abstract

OBJECTIVE:

The aim of this study was to investigate whether the thymidylate synthase (TYMS) 2R/3R and 6 bp I/D polymorphisms can predict the response to or toxicity of methotrexate (MTX) in patients with rheumatoid arthritis (RA).

METHODS:

We conducted a meta-analysis of studies on the association between the TYMS 2R/3R and 6 bp I/D polymorphisms and non-responsiveness to or toxicity of MTX in RA patients.

RESULTS:

A total of 11 studies involving 1613 patients were considered. Meta-analysis showed no association between the TYMS 2R/3R 3R allele and non-responsiveness to MTX therapy (odds ratio [OR] = 1.087, confidence interval [CI] = 0.682-1.731, p = 0.726). The meta-analysis indicated that there was no association between the TYMS 6 bp I/D D allele and non-responsiveness to MTX therapy (OR = 0.688, 95% CI = 0.281-1.683, p = 0.413). Meta-analysis revealed that the TYMS 2R/3R polymorphism was not associated with MTX toxicity, except for in a co-dominant model, and the TYMS 6 bp I/D polymorphism was not associated with MTX toxicity in all genetic models.

CONCLUSIONS:

This meta-analysis demonstrates that the TYMS 2R/3R and 6 bp I/D polymorphisms may not be associated with non-responsiveness to or toxicity of MTX therapy in RA patients.

KEYWORDS:

Methotrexate; Rheumatoid arthritis; TYMS polymorphism

PMID:
29380036
DOI:
10.1007/s00393-018-0419-4

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center